Effects of cilazapril on vascular structure and function in essential hypertension

Hypertension

Volumn 27, Issue 3 I, 1996, Pages 371-376

  Kiowski, Wolfgang ^a,b   Linder, Lilly ^a   Nuesch, Reto ^a   Martina, Benedikt ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

acetylcholine; angiotensin converting enzyme inhibitors; blood vessels; endothelium; hypertension, essential; vascular resistance; vasodilation

Indexed keywords

ACETYLCHOLINE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITROPRUSSIDE SODIUM;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM; ESSENTIAL HYPERTENSION; HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASODILATATION;

EID: 0029989647     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.3.371     Document Type: Article

References (50)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
2. Vanhoutte PM. Endothelium and control of vascular function. State-of-the-Art lecture. Hypertension. 1989;13:658-667.
3. Vane JR, Änggard EE, Botting RM. Regulatory functions of the endothelium. N Engl J Med. 1990;323:27-36.
4. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-1256.
5. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86:3375-3378.
6. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2: 997-1000.
7. Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, Buhler FR. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation. 1994;90:27-34.
8. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
9. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132-141.
10. Kannel WB. Office assessment of coronary candidates and risk factor insights from the Framingham study. J Hypertens. 1991; 9(suppl):958-972.
11. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
12. Panza JA, Quyyumi AA, Brush JEJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension (see comments). N Engl J Med. 1990;323:22-27.
13. Hirooka Y, Imaizumi T, Masaki H, Aando S, Harada S, Momohera M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 1992;20:175-180.
14. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilation in essential hypertension. N Engl J Med. 1994;330:1029-1035.
15. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025-1031.
16. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
17. Folkow B, Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
18. Dzau VJ, Gibbons G. Does hypertension potentiate atherosclerosis via vascular hypertrophy? J Cardiovasc Pharmacol. 1991;17:34-37.
19. Morishita R, Higaki J, Miyazaki M, Ogihara T. Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension. 1992;19(suppl II):II-62-II-67.
20. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension. 1990;16:532-540.
21. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17:626-635.
22. Schiffrin EL, Deng LY, Larochelle P. Effects of β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
23. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145-1151.
24. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994; 24:499-505.
25. Rosei EA, Rizzoni D, Castellano M, Porteri E, Zulli R, Muiesan MI, Bettoni G, Salvetti M, Muiesan P, Giulini M. Media:lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens. 1995;13:431-438.
26. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension. 1989;13:968-972.
27. Agabiti-Rosei E, Muiesan ML, Geri A, Romanelli G, Montani G, Muiesan G. Relation between cardiac hypertrophy and forearm vascular structural changes before and during long-term antihypertensive treatment. Am J Med. 1988;84(suppl 3A):125-128.
28. Mulvany MJ. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol. 1992;19(suppl 2):22-27.
29. Pedrinelli R, Spessot M, Salvetti A. Reactive hyperemia during short-term blood flow and pressure changes in the hypertensive forearm. J Hypertens. 1990;8:467-471.
30. Adams MA, Bobik A, Korner PI. Differential development of vascular and cardiac hypertrophy in genetic hypertension: relation to sympathetic function. Hypertension. 1989;14:191-202.
31. Mulvany MJ. Arc vascular abnormalities a primary cause or secondary consequence of hypertension? Hypertension. 1991;18(suppl I):I-52-I-57.
32. Kobrin I, Güntzel P, Viskoper R, Paran E, Zimlichman R. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. Drugs. 1991;41(suppl 1):31-36.
33. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension. 1987:9:178-187.
34. Asaad M, Antonaccio M. Vascular wall renin in spontaneously hypertensive rats: potential relevance to hypertension maintenance and antihypertensive effect of captopril. Hypertension. 1982;4: 487-493.
35. Adams MA, Bobik A, Korner PI. Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension. 1990;16:252-260.
36. Harrap SB, Van der Merve WM, Griffin SA, MacPherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension. 1990;16:603-614.
37. Lundin SA, Hallbäck-Nordlander ML. Regression of cardiovascular changes by antihypertensive therapy in spontaneously hypertensive rats. J Hypertens. 1984;2:11-18.
38. Kobayashi H, Sano T, Tarazi RC, Fouad-Tarazi FM. Effects of antihypertensive drugs on heart and resistance vessels. Cardiovasc Res. 1990;:24:137-143.
39. Kiowski W, Bühler F, van Brummelen P, Amann F. Plasma noradrenaline concentration and alpha-adrenoceptor-mediated vasoconstriction in normotensive and hypertensive man. Clin Sci. 1981; 60:483-489.
40. Bolli P, Kiowski W, Amann FW, Buhler FR. Adrenaline and enhanced vasoconstriction in patients with essential hypertension. Pharmacol Toxicol. 1988;63:781-788.
41. Hulthen UL, Bolli P, Amann FW, Kiowski W, Bühler FR. Enhanced vasodilation in essential hypertension by calcium channel blockade with verapamil. Hypertension. 1982;4(suppl II):II-26-II-31.
42. Lüscher TF. The endothelium and cardiovascular disease: a complex relation. N Engl J Med. 1994;330:108l-1082. Editorial.
43. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholester-olaemic patients by L-arginine. Lancet. 1991;338:1546-1550.
44. Lockette W, Olsuka Y, Carretero O. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension. 1986; 8(suppl II):II-61-II-66.
45. Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension. 1987;9(suppl III): III-193-III-197.
46. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89:2212-2218.
47. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
48. Shultz PJ, Raij L. Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations. Br J Clin Pharmacol. 1989;28(suppl 2):151-157.
49. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
50. Amann FW, Bolli P, Kiowski W, Bühler FR. Enhanced alpha-adrenoceptor-mediated vasoconstriction in essential hypertension. Hypertension. 1981;3(suppl I):I-119-I-123.